• SHIFT is the basis for a prognostic model for heart failure patients
• Ivabradine safely and significantly improves heart rate variability parameters
• The efficacy and safety of ivabradine is independent of baseline blood pressure
• Ivabradine’s clinical benefits in CHF are maintained with or without renal dysfunction
• Ivabradine improves clinical outcomes independently of heart failure severity
• Ivabradine is similarly effective in chronic heart failure patients with or without COPD
• Age does not limit the appropriate use of ivabradine in patients with chronic heart failure and systolic dysfunction